Table 1.
Baseline clinical factors by baseline vaccination status
| Fully vaccinated N (%) |
Partially vaccinated N (%) |
Unvaccinated N (%) |
|
|---|---|---|---|
| Total patients (N = 1787) | 54 (3) | 77 (4) | 1656 (93) |
| Median age, years (IQR) | 65.5 (57.0-72.8) | 68.0 (58.0-78.0) | 64.0 (54.0-74.0) |
| Female sex | 35 (65) | 38 (49) | 903 (55) |
| Non-Hispanic White | 38 (70) | 58 (75) | 999 (60) |
| ECOG performance status ≥2 | 9 (17) | 14 (18) | 224 (14) |
| Modified Charlson comorbidity index ≥2 | 17 (31) | 26 (34) | 413 (25) |
| Current or former smoker | 26 (48) | 33 (43) | 732 (44) |
| Hematologic malignancy | 19 (35) | 18 (23) | 339 (20) |
| Cancer status active and progressing | 10 (19) | 17 (22) | 237 (14) |
| Systemic treatment within 3 months | 30 (56) | 31 (40) | 720 (43) |
| Baseline prednisone dose-equivalent >10 mg/day | 9 (17) | <5 (<6)c | 117 (7) |
| ALC ≤1000/μl (not drawn/not available N = 902) | 25 (46) | 26 (34) | 469 (28) |
| COVID-19 vaccinationa | — | — | — |
| Ad26.COV2.S (Johnson & Johnson) | 10 (19)b | 5 (6) | — |
| mRNA-1273 (Moderna) | 22 (29) | — | |
| BNT162b2 (Pfizer-BioNTech) | 44 (81) | 33 (43) | — |
| COVID-19 infection severity | — | — | — |
| 30-day mortality | 7 (13) | <5 (<6)c | 160 (10) |
| Admitted to intensive care | 10 (19) | 11 (14) | 215 (13) |
| Hospitalized | 35 (65) | 45 (58) | 834 (50) |
ALC, absolute lymphocyte count; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range.
a
Numbers for partially vaccinated add up to <100% as 17 patients were vaccinated but reported as other or unknown type.
b
Numbers for AD26.COV2.S and mRNA-1273 are combined as n < 5 for one vaccination type, requiring masking per standard CCC19 protocol.
c
Numbers and percentages are masked for small cell counts per standard CCC19 protocol.